Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human T-lymphotropic virus type I infection.

A Manns1, M Hisada, L La Grenade

  • 1Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. mannsa@epndce.nci.nih.gov

Lancet (London, England)
|June 17, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chimeric Allografts Induced by Short-Term Treatment With Stem Cell-Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: A Study in Rats.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Effect of tongue position on masseter and temporalis electromyographic activity during swallowing and maximal voluntary clenching: a cross-sectional study.

Journal of oral rehabilitation·2014
Same author

The effect of tongue position and resulting vertical dimension on masticatory muscle activity. A cross-sectional study.

Journal of oral rehabilitation·2013
Same author

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.

Diabetes, obesity & metabolism·2013
Same author

Successful transplantation of reduced-sized rat alcoholic fatty livers made possible by mobilization of host stem cells.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2012
Same author

Mobilization of host stem cells enables long-term liver transplant acceptance in a strongly rejecting rat strain combination.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011

Human T-cell lymphotropic virus type I (HTLV-I) causes adult T-cell leukaemia/lymphoma and other serious conditions. Its full disease spectrum, transmission, and lack of treatment options highlight public health concerns.

Area of Science:

  • Virology and Immunology
  • Infectious Diseases
  • Neurodegenerative Disorders

Background:

  • Human T-cell lymphotropic virus type I (HTLV-I) is the first identified human retrovirus linked to malignancy.
  • HTLV-I is associated with adult T-cell leukaemia/lymphoma and non-malignant conditions like HTLV-I associated myelopathy (HAM/TSP), infective dermatitis, and uveitis.

Purpose of the Study:

  • To summarize the known disease spectrum of HTLV-I.
  • To highlight the global distribution and transmission routes of HTLV-I.
  • To underscore the current limitations in prevention and treatment for HTLV-I.

Main Methods:

  • Literature review and synthesis of existing research on HTLV-I.
  • Analysis of epidemiological data regarding HTLV-I prevalence and transmission.

Related Experiment Videos

Main Results:

  • HTLV-I is associated with a range of malignant and non-malignant diseases, with its full spectrum still under investigation.
  • Endemic foci are identified in the Caribbean and southern Japan, with mother-to-child, sexual, and blood transfusion being primary transmission routes.
  • There are currently no available vaccines or proven treatments for advanced HTLV-I disease.

Conclusions:

  • The known disease spectrum of HTLV-I is expanding, necessitating continued research.
  • Effective public health strategies are crucial due to efficient transmission routes.
  • Urgent development of vaccines and treatments for HTLV-I is required.